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Abstract
Background and aims: Smoking affects the course of disease in patients with ulcerative colitis 
(UC) and Crohn’s disease (CD). We aimed to study the association between smoking and extra-
intestinal manifestations (EIMs) in inflammatory bowel disease (IBD).
Methods: We cross-sectionally explored the association between smoking and EIMs in IBD in 
three cohort studies: (1) the COIN study, designed to estimate healthcare expenditures in IBD; (2) 
the Groningen study, focused on cigarette smoke exposure and disease behaviour in IBD; and (3) 
the JOINT study, evaluating joint and back manifestations in IBD.
Results: In the COIN, Groningen and JOINT cohorts, 3030, 797 and 225 patients were enrolled, 
of whom 16, 24 and 23.5% were current smokers, respectively. Chronic skin disorders and joint 
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manifestations were more prevalent in smoking IBD patients than in non-smokers (COIN, 39.1 vs 
29.8%, p <0.01; Groningen, 41.7 vs 30.0%, p <0.01) in both CD and UC. In the JOINT cohort, smoking 
was more prevalent in IBD patients with joint manifestations than in those without (30.3 vs 13.0%, 
p <0.01). EIMs appeared to be more prevalent in high- than in low-exposure smokers (56.0 vs 
37.1%, p = 0.10). After smoking cessation, the prevalence of EIMs in IBD patients rapidly decreased 
towards levels found in never smokers (lag time: COIN cohort, 1–2 years; Groningen cohort, within 
1 year).
Conclusions: There is a robust dose-dependent association between active smoking and EIMs 
in both CD and UC patients. Smoking cessation was found to result in a rapid reduction of EIM 
prevalence to levels encountered in never smokers.
Key Words:  Inflammatory bowel disease; extra-intestinal manifestations; smoking
1. Introduction
Inflammatory bowel disease (IBD) is a chronic intestinal disorder 
comprising Crohn’s disease (CD) and ulcerative colitis (UC). In 
Europe the incidence rates are currently estimated to be 5.4 per 
100 000 person-years for CD and 8.2 per 100 000 person-years for 
UC.1
IBD is frequently associated with extra-intestinal manifestations 
(EIMs). The most common EIMs involve the joints, the skin and the 
eyes.2 The prevalence of EIMs in IBD patients ranges from 6 to 38%, 
and patients with CD are more prone to the development of EIMs 
than UC patients.3–8
The influence of smoking on disease activity in patients with 
IBD is now well established. Remarkably, smoking affects the course 
of disease differently in CD and UC, having a negative effect on 
the course of CD and a beneficial effect in UC.8–10 The association 
between smoking and EIMs in IBD is currently largely undefined. 
As the burden of EIMs for these patients is high and its treatment 
remains a challenge, a better understanding of risk factors for EIMs 
in IBD is warranted. An increased prevalence of EIMs in smoking 
IBD patients was reported in two recent studies.11,12 These studies 
did not correct for disease activity and were not conclusive with 
respect to the potential difference between CD and UC. Importantly, 
no studies have been performed that are solely focused on the asso-
ciation between smoking and EIMs in IBD.
We hypothesized that EIMs are more prevalent in smoking CD 
patients, as smoking may induce an inflammatory response both 
inside and outside the gut. Because smoking is associated with a 
more benign disease course in UC, EIMs might be less prevalent in 
smoking UC patients.
The primary aim of the current cohort study was to examine 
the putative association between smoking and EIMs in IBD. Our 
secondary aims were to detect a possible dose–response relationship 
between smoking and EIMs and to test whether smoking was associ-
ated with specific phenotypes of joint manifestations in IBD.
2. Methods
2.1. Study design and study population
We explored the association between smoking and EIMs in three 
IBD cohorts.
The COIN (Costs of Inflammatory Bowel Disease in the 
Netherlands) study13 is a large multicentre cohort study initiated 
in 2010 to prospectively assess the quality of life and the direct 
and indirect IBD-related healthcare and non-healthcare costs. All 
patients from seven university medical centres and seven general 
hospitals aged 18 years or older were eligible for participation. This 
study is still ongoing.
The Groningen study was a prospective single-centre cohort 
study, mainly designed to evaluate the clinical effects of smoking on 
IBD.10 The cohort population consisted of consecutive IBD patients 
who visited the outpatient department of the University Medical 
Centre Groningen between January 1995 and October 2005. 
Patients with a concomitant liver transplantation were excluded.
The JOINT study14 was a single-centre prospective cohort study 
focused on IBD patients with and without back pain and/or periph-
eral joint complaints. The study population consisted of consecutive 
IBD patients who were systematically assessed by a multidiscipli-
nary team of gastroenterologists and rheumatologists at the Leiden 
University Medical Centre between July 2009 and February 2010. 
All included patients were followed for 12 months.
All three studies were approved by local medical ethics commit-
tees. More details on study designs can be found in the correspond-
ing references.10,13,14
2.2. Data collection
For the COIN cohort, participants were invited to fill out a base-
line questionnaire followed by 3-monthly questionnaires. To control 
equality between the cohort population and the patients who did 
not respond, demographics and disease characteristics were com-
pared between responders and non-responders.13 For the current 
study, demographic data, smoking status (both current and previous, 
including date of smoking cessation, if applicable), EIMs and disease 
severity (self-reported flares) were extracted at baseline and medica-
tion use was extracted after 3 months of follow-up.
In the Groningen cohort, patients received a detailed question-
naire about their smoking behaviour. For the patients who returned 
the questionnaire, clinical characteristics and outcome variables 
were assessed by both a retrospective analysis of medical records and 
the collection of outcome variables during follow-up. For the cur-
rent study, we focused on information on smoking behaviour (both 
current and previous, including number of pack-years15 and date of 
smoking cessation, if applicable) and EIMs from medical records.
In the JOINT cohort, data on medical history (EIMs, family his-
tory and medication use), physical examination (palpation of the 
joints, entheses and digits), laboratory tests (C-reactive protein and 
HLA-B27) and radiological examinations of affected joints were col-
lected from all enrolled patients. Based on these assessments, patients 
were categorized into two study arms: (1) patients with joint and/or 
back pain for ≥3 months and/or peripheral joint pain or swelling 
during the last year; and (2) patients without joint and/or back pain. 
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Peripheral arthritis was defined as the presence of both pain and 
swelling in one or more joints and arthralgia was defined as non-
inflammatory joint pain. At baseline, demographic characteristics 
(including current smoking status) were collected.
2.3. Definition of extra-intestinal manifestations
In the COIN cohort, EIMs were defined as the presence of self-
reported joint complaints (arthritis and chronic back pain) and/or 
chronic skin disorders. In the Groningen cohort, EIMs were defined 
as joint complaints (arthralgia, enthesitis, arthritis, sacro-iliitis and 
ankylosing spondylitis) and/or skin disorders (erythema nodosum, 
pyoderma gangrenosum, psoriasis and hidradenitis suppurativa), as 
extracted from medical records, confirmed by medical specialists. 
The JOINT study was focused on joint manifestations, which were 
objectified by an extensive assessment by medical specialists.
2.4. Data analysis
The association between smoking and EIMs was cross-sectionally 
analysed in all three cohorts separately. We compared the prevalence 
of EIMs between smokers, non-smokers and ex-smokers using the χ2 
test or Fisher’s exact test, as appropriate. In the COIN and Groningen 
cohorts, we performed univariable and multivariable logistic regres-
sion analyses to test whether current smoking and ex-smoking were 
independent predictors of EIMs. Multivariable analysis was per-
formed with co-variables with a p value <0.20 in the univariable 
analysis. Furthermore, we investigated the putative dose–response 
relationship between smoking and EIMs in the Groningen cohort. 
First, we compared the prevalence of EIMs between high (>10 pack-
years) and low (≤10 pack-years) exposure smokers using the χ2 test. 
Second, we compared the prevalence of EIMs between inclining lev-
els of smoke exposure, measured by pack-years,15,16 using one-way 
ANOVA with the Tukey and/or Games–Howell post hoc multiple 
comparison test for trends. Participants in the JOINT cohort were 
categorized based on the presence or absence of peripheral joint 
manifestations or back pain. Therefore, we compared the prevalence 
of smoking between patients with and without joint manifestations 
in this cohort using the χ2 test. Moreover, we explored the associa-
tion between smoking and specific phenotypes of joint manifesta-
tions by comparing the distribution of phenotypes between smokers 
and non-smokers using the χ2 test. P-values < 0.05 were considered 
statistically significant. All statistical analyses were performed using 
SPSS version 21 (Armonk, NY).
3. Results
3.1. Study population
In the COIN cohort 3030 patients were enrolled; 16% of the 
patients currently smoked (CD 21.1%, UC 9.0%). There were no 
statistically significant differences between responders and non-
responders.13 In the Groningen cohort 797 IBD patients returned 
the questionnaire (97.2% response rate), of whom 24.0% were cur-
rent smokers (CD 33.2%, UC 12.6%). In the JOINT cohort 255 
patients (155 IBD patients with joint complaints, 100 without joint 
complaints) were enrolled. In this cohort 23.5% were current smok-
ers (CD 27.4%, UC 13.0%). In the COIN cohort, ex-smoking CD 
and UC patients quit smoking a median of 10 years (interquartile 
range [IQR] 5–18) and 14 years (IQR 8–25) before inclusion. In the 
Groningen cohort, ex-smoking CD and UC patients quit smoking a 
median of 7 (IQR 2–14) and 13 (IQR 3–23) years before inclusion. 
In the JOINT cohort, ex-smoking CD and UC patients quit smoking 
a median of 10 years (IQR 3–19) and 14 years (IQR 5–27) before 
inclusion. Available baseline characteristics of all study participants 
are listed in Table 1.
3.2. Association between smoking and EIMs in IBD
The overall prevalence of EIMs in IBD was 31.3% in the COIN 
cohort and 32.3% in the Groningen cohort. EIMs were significantly 
more prevalent in the smoking IBD population than in non-smoking 
patients (COIN cohort, 39.1 vs 29.8%, p < 0.01; Groningen cohort, 
41.7 vs 30.0%, p  <  0.01) (Figure  1). EIMs were more prevalent 
in current smokers than in never smokers (COIN and Groningen 
cohort, p < 0.01), and in the Groningen cohort also compared with 
ex-smokers (p < 0.01) (Table 2). In the COIN cohort smoking was 
associated with EIMs in both CD and UC patients, although more 
predominantly so in CD. Joint manifestations appeared to be more 
strongly associated with smoking than skin disorders.
3.3. Prevalence of smoking in IBD patients with 
joint complaints
In the JOINT cohort, smoking was more prevalent in IBD patients 
with joint manifestations than in patients without joint manifesta-
tions (30.3 vs 13%, p < 0.01). This association was found in both 
CD and UC patients (CD, 33.9 vs 15.4%, p  <  0.01; UC, 17.6 vs 
8.6%, p  =  0.03). Joint manifestations in smokers were diagnosed 
after a mean of 17 years of tobacco exposure (standard deviation 
13 years). Smoking was not associated with a specific localization of 
joint manifestations (axial pain, 8.5% in smokers vs 8.3% in non-
smokers, p = 0.53; peripheral joint manifestations, 44.7% in smokers 
vs 54.6% in non-smokers, p = 0.49). However, smoking IBD patients 
more often experienced a combination of both axial and peripheral 
joint manifestations (46.9 vs 37.0%, p = 0.01). Smoking was not pri-
marily associated with peripheral arthritis, as the prevalence was not 
significantly higher in smoking IBD patients (p = 0.34). Arthralgia 
was found to be more prevalent in smoking IBD patients (48.3 vs 
32.3% p = 0.02), especially in CD.
3.4. Multivariable analysis for the presence of EIMs 
in IBD
Adjusted for demographic data and disease severity, active smoking 
was associated with the presence of EIMs with an odds ratio (OR) 
of 1.52 in CD patients (95% confidence interval [CI] 1.15–2.01) and 
1.75 in UC patients (1.07–2.84) of the COIN cohort (Supplementary 
Table  1). Female gender and higher age were also independently 
associated with the presence of EIMs in both CD and UC. The previ-
ous use of biologicals and a low level of education were found to be 
independent risk factors for EIMs in CD, and ex-smoking was an 
independent factor for EIMs in UC (OR 1.41, 95% CI 1.03–1.92). 
In the Groningen cohort, smoking was not an independent factor for 
EIMs in CD and UC (Supplementary Table 2). In this cohort, a low 
education level was found to be independently associated with EIMs 
in UC (adjusted OR 2.31, 95% CI 1.14– 4.70)
3.5. Dose–response relationship between smoking 
and EIMs in IBD
In the Groningen cohort, complete information on the quantity of 
total tobacco exposure was available for analysis in 95 currently 
smoking IBD patients (70 CD, 22 UC and 3 IBD unclassified). 
Although not statistically significant, EIMs appeared to be more 
prevalent in high-exposure smokers (>10 pack-years) than in low-
exposure smokers (≤10 pack-years), which applied to CD but not 
to UC patients (IBD, 56.0 vs 37.1%, p = 0.10; CD, 64.7 vs 39.2%, 
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p = 0.07; UC, 20.0 vs 33.3%, p = 0.57). Based on a subdivision of 
smoking patients into light smokers (0.1–20.0 pack-years), moder-
ate smokers (20.1–40.0 pack-years) and heavy smokers (>40 pack-
years), the prevalence of EIMs appeared to increase with higher 
levels of smoke exposure (IBD, 37.8, 50.0 and 60.0%, respectively; 
CD, 41.7, 50.0 and 100.0%). Meaningful statistical analysis in UC 
could not be performed due to the low number of cases. For the total 
IBD population, no statistical significant trend was found, but for 
CD a statistical significant difference in prevalence of EIMs between 
light smokers and heavy smokers was found (p < 0.05).
3.6. EIMs in ex-smoking IBD patients
The prevalence of EIMs in ex-smoking IBD patients and in patients 
who never smoked was comparable to that in the Groningen cohort 
Table 1. Baseline characteristics.
COIN cohort Groningen cohort JOINT cohort
Number of patients 3030 797 255
Demographics
 Male gender, n (%) 1325 (43.7) 326 (40.9) 97 (38.0)
 Type of IBD, n (%)
  Crohn’s disease 1558 (51.4) 428 (53.7) 186 (72.9)
  Ulcerative colitis 1054 (34.8) 307 (38.5) 69 (27.1)
  Unspecified 418 (13.8) 62 (7.8) 0 (0.0)
 Age, years, mean (SD) 51.6 (13.7) 41.0 (14.5) 43.1 (13.5)
 Low education level, n (%) 1898 (62.6) 468 (58.7) 135 (52.9)
 Currently employed, n (%) 1557 (51.4) 470 (59.0) 157 (61.6)
 Smoking status, n (%), IBD, CD, UC
  Current 486 (16.0), 329 (21.1), 95 (9.0) 188 (24.0), 139 (33.2), 38 (12.6) 60 (23.5), 51 (27.4), 9 (13.0)
  Never 1605 (53.0), 781 (50.1), 603 (57.1) 304 (38.9), 133 (31.7), 142 (47.0) 98 (38.4), 61 (32.8), 37 (53.6)
  Ex 939 (31.0), 448 (28.8), 358 (33.9) 290 (37.1), 147 (35.1), 122 (40.4) 97 (38.0), 74 (39.8), 23 (33.3)
Disease characteristics, Montreal classification, n (%)
 Location, n (%)
  L1, ileal – 99 (33.9) 46 (24.7)
  L2, colonic – 62 (21.2) 40 (21.5)
  L3, ileocolonic – 105 (36.0) 83 (44.6)
  L4, upper – 4 (1.4) 2 (1.1)
  L1–3 + L4 – 22 (7.5) 15 (8.1)
 Behaviour of CD
  B1, non-stricturing/penetrating – 130 (42.2) 109 (58.6)
  B2, stricturing – 46 (14.9) 38 (20.4)
  B3, penetrating + perianal disease – 132 (42.9) 39 (21.0), 55 (30.0)
 Extension of UC, n (%)
  E1, ulcerative proctitis – 33 (15.7) 7 (10.1)
  E2, left-sided UC – 63 (30.0) 23 (33.3)
  E3, extensive UC (pancolitis) – 114 (54.3) 39 (56.5)
 UC severity, n (%)
  S1, clinical remission – 22 (7.2) –
  S2, mild – 64 (20.8) –
  S3, moderate – 64 (20.8) –
  S4, severe – 61 (19.8) –
  Unknown – 96 (31.3) –
Disease location, n (%)
 Small bowel 306 (19.6) – –
 Large bowel 431 (27.7) – –
 Small and large bowel 768 (49.3) – –
Penetrating disease in CD, n (%) 814 (52.2)
Disease in remission, n (%) 2549 (84.2) – 152 (59.6)
Stoma, n (%) 300 (9.9) 102 (12.8) 20 (7.8)
Pouch n (%) 167 (5.5) 9 (1.1) 13 (5.1)
Abdominal surgery in the past, n (%) 1143 (37.7) 250 (45.2) 107 (42.0)
Medication use, n (%), CD, UC*
 5-ASA 307 (23.5), 596 (65.2) 27 (6.3), 144 (46.9) 18 (9.7), 33 (47.8)
 Steroids 134 (10.2), 70 (7.6) 63 (14.7), 30 (9.8) 9 (4.8), 5 (7.2)
 Immunosuppressive drugs, (Aza + 
6MP +MTX)
463 (35.4), 203 (22.2) 155 (36.2), 65 (21.1) 43 (23.1), 12 (17.4)
 Anti-TNF 299 (22.9), 35 (3.8) 114 (26.6), 11 (3.6) 66 (35.5), 6 (8.7)
 None 337 (25.8), 198 (21.7) 57 (13.3), 44 (14.3) 50 (26.9), 13 (18.8)
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; ASA, aminosalicylic acid; Aza, azathioprine; 6MP, 6-mercaptopurine; MTX, 
methotrexate; TNF, tumour necrosis factor.
*At 3 months of follow-up.
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(30.5 vs 29.3%, p  =  0.95), which applied to both CD and UC. In 
the COIN cohort, the prevalence of EIMs was higher in ex-smoking 
patients than in never smokers (34.6 vs 26.9%, p < 0.01), which also 
applied to both CD and UC. However, when comparing the prevalence 
of EIMs between patients who recently quitted smoking and patients 
who quitted longer ago, we observed a rapid decline in prevalence 
towards levels encountered in never smokers in both cohorts. In the 
Groningen cohort, IBD patients who quitted smoking >3 months ago 
appeared to have EIMs less often than patients who stopped smoking 
<3 months before inclusion (33.0 [n = 60] vs 57.1% [n = 7], p = 0.07). 
In the COIN cohort, the prevalence of EIMs in the ex-smoking IBD 
population appeared to decline if smoking was stopped for >1 year, 
since the prevalence of EIMs was 42.9% (n = 3) in patients who quit-
ted smoking <1 year before inclusion compared with 30.9% (n = 17) 
in patients who quitted between 1 and 2  years before inclusion, 
although the difference was not statistically significant (p = 0.52).
4. Discussion
This study, encompassing results from three different cohorts, has 
demonstrated a strong association between smoking and EIMs in 
IBD, and indicates a dose–response relationship, as EIMs appear 
to be more prevalent in heavy-smoking patients. Interestingly, the 
prevalence rates of EIMs rapidly declined to levels encountered in 
never-smoking patients when patients quit smoking.
We found a higher prevalence of joint manifestations and chronic 
skin disorders in smoking CD and UC patients. Moreover, we found 
smoking to be significantly more common in both CD and UC 
patients with joint manifestations. Current data on the association of 
smoking and EIMs are inconclusive. While some studies on risk fac-
tors for EIMs found smoking to be associated with EIMs in CD but 
not in UC patients,11,17 other studies found an increased prevalence 
of ocular EIMs,18 spondylarthropathy and cutaneous complica-
tions18 in smoking UC patients. Two studies reported no association 
between smoking and EIMs in CD.19,20 The strength of the present 
study is that we were able to focus on smoking and EIMs in IBD in 
three different cohorts, encompassing more than 4000 patients. This 
cohort corroborated previous results and provided further insight 
into several aspects of this association. For the first time, a dose–
response relationship was suggested. We could not clearly identify 
an association with specific phenotypes of joint manifestations, how-
ever. Furthermore, our data allowed us to correct for possible con-
founders, such as disease severity and the previous use of biologicals 
or immunosuppressive drugs, which had not been evaluated before.
Table 2. Association between smoking and extra-intestinal manifestations in inflammatory bowel disease.












 Total EIMs COIN 190 (39.1) 432 (26.9) 325 (34.6) <0.01 <0.01 0.10
Groningen 75 (41.7) 87 (29.3) 86 (30.5) <0.01 <0.01 0.01
 Joint complaints COIN 134 (27.6) 290 (18.1) 241 (25.7) < 0.01 <0.01 0.44
Groningen 69 (42.3) 84 (31.6) 84 (32.4) 0.02 0.02 0.04
 Chronic skin disorders COIN 82 (16.9) 207 (12.9) 128 (13.6) 0.03 0.03 0.10
Groningen 12 (6.8) 8 (2.7) 11 (4.0) <0.05 0.04 0.19
Crohn’s disease
 Total EIMs COIN 140 (42.6) 235 (30.1) 167 (37.3) <0.01 <0.01 0.14
Groningen 64 (47.1) 51 (38.6) 58 (39.5) 0.12 0.16 0.20
 Joint complaints COIN 101 (30.7) 155 (19.8) 117 (26.1) <0.01 <0.01 0.16
Groningen 58 (46.4) 49 (39.5) 58 (41.4) 0.26 0.27 0.42
 Chronic skin disorders COIN 60 (18.2) 117 (15.0) 76 (17.0) 0.27 0.18 0.65
Groningen 12 (9.0) 6 (4.6) 8 (5.6) 0.13 0.15 0.27
Ulcerative colitis
 Total EIMs COIN 32 (33.7) 136 (22.6) 115 (32.1) 0.11 0.02 0.77
Groningen 9 (25.7) 27 (19.6) 26 (22.8) 0.56 0.42 0.72
 Joint complaints COIN 24 (25.3) 92 (15.3) 86 (24.0) 0.11 0.02 0.80
Groningen 9 (31.0) 26 (21.7) 24 (24.0) 0.34 0.29 0.45
 Chronic skin disorders COIN 12 (12.6) 63 (10.3) 38 (10.6) 0.50 0.49 0.58
Groningen 0 (0.0) 2 (1.5) 3 (2.7) 0.39 1.00 1.00






















































































Figure 1. Prevalence of extra-intestinal manifestations in smoking versus non-smoking inflammatory bowel disease patients.







460 M. Severs et al.
The diverse effects of smoking on the clinical course in CD and 
UC are well established in the literature,9,10,21 but the underlying 
mechanisms are incompletely understood. In the multivariable anal-
yses of the COIN data, smoking was an independent factor for the 
presence of EIMs in both CD and UC, irrespective of disease severity. 
Based on a predefined statistical significance level of p < 0.05, the 
analyses in the Groningen cohort could not confirm these results, 
probably due to a smaller number of patients.22 The molecular 
mechanisms through which the association between smoking and 
EIMs are established in UC and CD might be based on different 
pathways. It has been postulated that the opposing effects of smok-
ing on the alimentary tract can be explained by differential effects 
on dendritic cells.23 Furthermore, in mice smoking is associated with 
intestinal barrier dysfunction in the small intestine, but not in the 
large intestine, indicating different responses in ileal and colonic epi-
thelial cells.24
Apart from smoking, female gender, greater age and a low level 
of education were also associated with EIMs. Female gender and 
greater age were previously identified as risk factors for EIMs in 
IBD.20 As for low educational level, this association has not been 
described before. It can be speculated that worse control of disease 
and/or other environmental factors are involved in these patients. 
Of note, smoking was associated with EIMs independently of 
educational level.
Smoking has been identified as one of the most important extrin-
sic factors for the development and severity of rheumatoid arthri-
tis (RA).25–27 The pathophysiology of RA in smokers is believed 
to include oxidative stress, systemic inflammation, autoantibody 
formation and epigenetic changes, such as DNA methylation.28 
Moreover, smoking has been reported to be the main predictor of 
severe extra-articular manifestations in RA, such as rheumatoid 
vasculitis, polyneuropathy and pleuritis.29–32 Both in CD and in RA, 
smoking has been associated with a poor response to anti-tumour 
necrosis factor (TNF) treatment.33–35 Smoking has also been linked 
to a more severe disease course in psoriasis,36,37 which is thought to 
be caused by smoking-induced oxidative damage along with insuffi-
cient capacity of antioxidant mechanisms.38 Similar pathways might 
underlie the association of smoking with EIMs in IBD, although at 
present this assumption cannot be substantiated.
Smoking cessation may be beneficial in IBD patients with EIMs, 
as in both the COIN cohort and the Groningen cohort we observed 
a rapid decrease in prevalence rates of EIMs after smoking cessation 
towards levels seen in never smokers. The beneficial effect of smok-
ing cessation on the clinical course of disease in CD patients has been 
reported previously,39 but its effect on EIMs has never been demon-
strated before. Whether the relationship between smoking cessation 
and a decline of EIMs is causal cannot be deduced from our data.
Some aspects of our findings need consideration. The results of 
the COIN study are based on self-reported data, which could have 
led to over- or underreporting of actual EIMs. However, the inter-
nal validity of this study seems to be robust13 and the accuracy of 
responses to health-related questionnaires from patients with IBD 
is generally high.40 Moreover, the prevalences of EIMs in the COIN 
and Groningen cohorts were very similar (31.3% and 32.3% respec-
tively), and our observations are in line with those described in the 
literature.3–7,41 The JOINT cohort was designed to study different 
aspects of joint complaints in IBD. Therefore, selection bias might 
have occurred in this cohort. For this reason, we analysed the results 
of this study separately and refrained from comparing the presence 
of skin disorders or eye diseases between smokers and non-smokers. 
Recall bias may be present for the number of pack-years per patient 
in the Groningen cohort. Self-reported smoking behaviour, however, 
has been rated as reliable in the literature, although in some stud-
ies a trend towards underestimation of total smoke exposure has 
been found.42,43 A relatively small number (95) of currently smok-
ing patients adequately reported their exact total smoke exposure. 
In a larger cohort, a dose–response relationship regarding smoking 
and EIMs might have reached statistical significance, but for now 
only a statistically significant trend could be detected in CD patients. 
Finally, the three examined studies differed in their baseline charac-
teristics and definitions of EIMs. For example, the number of cur-
rently smoking CD patients was highest in the Groningen cohort, 
the mean age of all patients was highest in the COIN cohort, and 
the JOINT cohort had a relatively high number of anti-TNFα users. 
EIMs were collected by self-report in the COIN study, extracted 
from medical records in the Groningen study and objectified by an 
extensive medical assessment in the JOINT study. However, regard-
less of the differences between the cohorts, the analyses of all cohorts 
separately led to the same conclusion with respect to the association 
between smoking and EIMs in IBD.
In conclusion, we have demonstrated a positive association 
between smoking and EIMs in IBD in three different cohorts, in both 
CD and UC patients. Our data suggest a dose–response relation-
ship regarding smoking behaviour. Most importantly, the prevalence 
of EIMs rapidly decreases towards levels found in never-smoking 
patients after smoking cessation. As EIMs frequently complicate the 
clinical course of IBD, clinicians should be aware that smoking ces-
sation might reduce the burden of EIMs in these patients.
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